CONTEMPORARY VIEWS OF THE PATHOGENESIS AND CLASSIFICATION OF ROSACEA

DOI: https://doi.org/10.29296/25877305-2019-03-03
Download full text PDF
Issue: 
3
Year: 
2019

Professor E. Snarskaya, MD; T. Rusina I.M. Sechenov First Moscow State Medical University (Sechenov University)

The paper reviews the literature on the variants of the pathogenesis of rosacea. It considers the epidemiology and prevalence of this pathology in the population and a classification and indi-cates the factors that provoke the disease, as well as the relationships of rosacea to genetic factors, to the action of microorganisms, to dysfunction of the digestive tract, to diseases of the endocrine and nervous systems, and to a change in immune status.
Keywords: 
dermatology
rosacea
pathogenesis
classification
review

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Butov Ju.S., Skripkin O.K., Ivanov O.L. Dermatovenerologija / M.: GEOTAR-Media, 2013. [Butov Yu.S., Skripkin O.K., Ivanov O.L. Dermatovenerologiya / M.: GEOTAR-Media, 2013 (in Russ.)].
  2. Kathanova O.A., Kathanov A.M., Stenin A.V. Kompleksnaja terapija akneformnyh dermatozov // Eksperim. i klin. dermatokosmetol. – 2014; 2: 12–8 [Katkhanova O.A., Katkhanov A.M., Stenin A.V. Combination therapy for acneiform dermatoses // Eksperimental’naya i klinicheskaya dermatokosmetologiya. – 2014; 2: 12–8 (in Russ.)].
  3. Olisova O.Ju., Kochergin N.G., Smirnova E.A. Innovatsii v naruzhnoj terapii rozatsea // Rossijskij zhurnal kozhnyh i venericheskih boleznej. – 2017; 20 (5): 270–4 [Olisova O.Yu., Kochergin N.G., Smirnova E.A. Innovations to topical therapy of rosacea // Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. – 2017; 20 (5): 270–4 (in Russ.)].
  4. Potekaev N.N., Demidova L.M., Shuginina E.A. Mikrotokovaja terapija: perspektivy primenenija v kosmetologii; rol' mikrotokov v lechenii rozatsea // Vestnik esteticheskoj meditsiny. – 2010; 9 (3): 6–12 [Potekayev N.N., Demidova L.M., Shugunina E.A. Microcurrent therapy: application perspective in cosmetology; microcurrents’ role in healing patients with rosacea // Vestnik esteticheskoy meditsiny. – 2010; 9 (3): 6–12 (in Russ.)] .
  5. Svirschevskaja E.V., Matushevskaja E.V., Matushevskaja Ju.I. Aktual'nye voprosy patogeneaza i terapii rozatsea // Klinicheskaja dermatologija i venerologija. – 2017; 4: 4–12 [Svirshchevskaya E.V., Matushevskaya E.V., Matushevskaya Yu.I. Modern questions in rosacea pathogenesis and therapy // Klinicheskaya dermatologiya i venerologiya. – 2017; 4: 4–12 (in Russ.)] DOI: 10.17116/klinderma20171644-13.
  6. Abram K., Silm H., Maaroos H. et al. Risk factors associated with rosacea // J. Eur. Acad. Dermatol. Venereol. – 2010; 24: 565–71.
  7. Abram. K., Silm H., Oona M. Prevalence of rosacea in an Estonian working population using a standard classification // Acta Derm. Venereol. – 2010; 90: 269–73.
  8. Ansel J., Armstrong C., Song I. et al Interactions of the skin and nervous system // J. Investig. Dermatol. Symp. Proc. – 1997; 2: 23–6.
  9. Bhatia N., Del Rosso J. Optimal management of papulopustular rosacea: rationale for combination therapy // J. Drugs Dermatol. – 2012; 11 (7): 838–44.
  10. Chang A., Raber I., Xu J. et al. Assessment of the genetic basis of rosacea by genome-wide association study // J. Invest. Dermatol. – 2015; 135: 1548–55.
  11. Chen Y., Moore C., Zhang J. et al. TRPV4 moves toward center-fold in rosacea pathogenesis // J. Invest. Dermatol. – 2017; 137: 801–4.
  12. Crawford G., Pelle M., James W. Rosacea: I. Etiology, pathogenesis, and subtype classification // J Am. Acad. Dermatol. – 2004; 51: 327–41.
  13. Del Rosso J. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema // J. Clin. Aesthet. Dermatol. – 2012; 5: 16–25.
  14. Dirschka T., Tronnier H., Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis // Br. J. Dermatol. – 2004; 150: 1136–41.
  15. Duman N., Ersoy Evans S., Atakan N. Rosacea and cardiovascular risk factors: a case control study // J. Eur. Acad. Dermatol. Venereol. – 2014; 28: 1165–9.
  16. Egeberg A., Hansen P., Gislason G. et al. Patients with rosacea have increased risk of depression and anxiety disorders: A danish nationwide cohort study // Dermatology. – 2016; 232: 208–13.
  17. Ekiz O., Balta I., Sen B.B. et al. Vitamin D status in patients with rosacea // Cutan Ocul. Toxicol. – 2014; 33 (1): 60–2.
  18. Gerber P., Buhren B., Steinhoff M. et al. Rosacea: The cytokine and chemokine network // J. Investig. Dermatol. Symp. Proc. – 2011; 15: 40–7.
  19. Gravina A., Federico A., Ruocco E. et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea // United Eur. Gastroenterol. J. – 2015; 3: 17–24.
  20. Guzman-Sanchez D., Ishiuji Y., Patel T. et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea // J. Am. Acad. Dermatol. – 2007; 57: 800–5.
  21. Halder R., Brooks H., Callender V. Acne in ethnic skin // Dermatol. Clin. – 2003; 21 (4): 609–15.
  22. Helfrich Y., Maier L., Cui Y. et al. Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging // JAMA Dermatol. – 2015; 151: 825–36.
  23. Herr H., You C. Relationship between Helicobacter pylori and rosacea: It may be a myth // J. Korean Med. Sci. – 2000; 15: 551–4.
  24. Del Rosso J. Rozatsea kozhi: patogenez, klinicheskie projavlenija, sovremennye rekomendatsii po taktike vedenija patsientov // Vestn. dermatol. i venerol. – 201; 2: 21–31 [Del Rosso J. Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management // Vestnik dermatologii i venerologii. – 2016; 2: 21–31 (In Russ.)]. https://doi.org/10.25208/0042-4609-2016-0-2-21-31.
  25. Kyriakis K., Palamaras I., Terzoudi S. et al. Epidemiologic aspects of rosacea // J. Am. Acad. Dermatol. – 2005; 53: 918–9.
  26. Li S., Cho E., Drucker A. et al. Alcohol Intake and Risk of Rosacea in US Women // J. Am. Acad. Dermatol. – 2017; 76: 1061–7.
  27. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host response // Nature. – 2006; 442: 39–44.
  28. Motley R., Barton S., Marks R. The signifi cance of telangiectasia in rosacea. In: Acne and Related Disorders: An International Symposium/ Wales: Martin Dunitz: Cardiff, 1989; p. 339–44.
  29. Muto Y., Wang Z., Vanderberghe M. et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea // J. Invest. Dermatol. – 2014; 134: 2728–36.
  30. Peters E. Stressed skin? – A molecular psychosomatic update on stress-causes and effects in dermatologic diseases // J. Dtsch. Dermatol. Ges. – 2016; 14: 233–52.
  31. Rainer B., Fischer A., Luz Felipe da Silva D. et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study // J. Am. Acad. Dermatol. – 2015; 73: 604–8.
  32. Ramelet A. Rosacea: a reaction pattern associated with ocular lesions and migraine? // Arch. Dermatol. – 1994; 130: 1448.
  33. Ramtin Kassir, Aparanjita Kolluru, Martin Kassir. Intense pulsed light for the treatment of Rosacea and Telangiectasias //J. Cosmetic Laser Ther. – 2006; 13 (5): 216–22.
  34. Rice W., Weiss S. Regulation of proteolysis at the neutrophilsubstrate interface by secretory leukoprotease inhibitor // Science. – 1990; 249: 178–81.
  35. Rios-Yuil J., Mercadillo-Perez P. Evaluation of Demodex folliculorum as a Risk Factor for the Diagnosis of Rosacea In Skin Biopsies. Mexico’s General Hospital (1975–2010) // Indian J. Dermatol. – 2013; 58: 157.
  36. Salzer S., Kresse S., Hirai Y. et al. Cathelicidin peptide LL-37 increases UVBtriggered inflammasome activation: possible implications for rosacea // J. Dermatol. Sci. – 2014; 76: 173–9.
  37. Schwab V., Sulk M., Seeliger S. et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea // J. Investig. Dermatol. Symp. Proc. – 2011; 15: 53–62.
  38. Steinhoff M., Schauber J., Leyden J. New insights into rosacea pathophysiology: a review of recent findings // J. Am. Acad. Dermatol. – 2013; 69: 15–26.
  39. Sulk M., Seeliger S., Aubert J. et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea // J. Invest. Dermatol. – 2012; 132: 1253–62.
  40. Two A., Wu W., Gallo R. et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors // J. Am. Acad. Dermatol. – 2015; 72: 749–58; quiz 59–60.
  41. Vieira A., Mannis M. Ocular rosacea: Common and commonly missed // J. Am. Acad. Dermatol. – 2013; 69: 36–41.
  42. Wang T., Nestel F., Bourdeau V. et al. Cutting edge: 1,25-dihydroxy vitamin D3 is a direct inducer of antimicrobial peptide gene expression // J. Immunol. – 2004; 73 (5): 2909–12.
  43. West J., Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease // Lancet. – 1992; 340: 762–7.
  44. Wilkin J., Dahl M., Detmar M. et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea // J. Am. Acad. Dermatol. – 2002; 46: 584–7.
  45. Wilkin J. Oral thermal-induced flushing in erythematotelangiectatic rosacea // J. Inves.t Derm. – 1981; 76: 15–8.
  46. Wollina U. Recent advances in the understanding and management of rosacea // F1000Prime Rep. – 2014; 6: 50.
  47. Yamasaki K., Gallo R. The molecular pathology of rosacea // J. Dermatol. Sci. – 2009; 55: 77–81.
  48. Melnik B. Rosacea: The blessing of the celts – an approach to pathogenesis through translational research // Acta Derm. Venereol. – 2016; 96 (2): 147–56.